Anti-Xa Levels in Critically Ill Patients Receiving Low-molecular-weight Heparin for Thromboprophylaxis in China

Southeast University, China

Status: Unknown

Conditions: Critically Ill; Anti-Xa

Treatments: Diagnostic Test: anti Xa level

Study type: Observational

Funder types: Other

Identifiers

NCT03311984

Anti-Xa Level

Details and patient eligibility

About

Critically ill Patients are at high risk to develop deep venous thrombosis. However, despite receiving of a standard dose of Low-molecular-weight Heparin（LMWH）, many patients still develop life-threatening embolism. The purpose of this study is to evaluate the anti-Xa levels of different dosing regimens of LMWH in critically ill patients in China.

Enrollment: 200 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Adult Critically ill patients

Exclusion criteria

• Contraindication to use of LMWH. Intracranial bleeding/stroke, hematoma or bleeding disorder. Use Heparin anticoagulant therapy

Trial design

200 participants in 2 patient groups

LMWH qd

Description:

receiving Low-molecular-weight Heparin（LMWH）qd

Treatment:

Diagnostic Test: anti Xa level

LMWH q12h

Description:

receiving Low-molecular-weight Heparin（LMWH）q12h

Treatment:

Diagnostic Test: anti Xa level